Skip Navigation

JNCI Journal of the National Cancer Institute 2004 96(15):1183; doi:10.1093/jnci/djh234
© 2004 by Oxford University Press
This Article
Right arrow Full Text Freely available
Right arrow FREE Full Text (PDF) Freely available
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Search for citing articles in:
ISI Web of Science (4)
Right arrow Request Permissions
Google Scholar
Right arrow Articles by Winquist, E.
Right arrow Articles by Berry, S.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Winquist, E.
Right arrow Articles by Berry, S.
Related Collections
Right arrowResponse to this Correspondence
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

© 2004 Oxford University Press

CORRESPONDENCE

Re: A Randomized, Placebo-Controlled Trial of Zoledronic Acid in Patients With Hormone-Refractory Metastatic Prostate Carcinoma

Eric Winquist, Scott Berry

Affiliations of authors: London Regional Cancer Centre, London, Ontario, Canada (EW); Toronto-Sunnybrook Regional Cancer Centre, Toronto, Ontario, Canada (SB)

Correspondence to: Eric Winquist, MD, MSc, FRCP(C) FACP, London Regional Cancer Centre, 790 Commissioners Road East, London, Ontario, Canada N6A 4L6 (e-mail: eric.winquist@lrcc.on.ca)

The first 10% of the full text of this article appears below.

The results of the well-conducted trial by Saad et al. (1) have prompted many to consider routine use of zoledronic acid to reduce the incidence of skeletal-related events in minimally symptomatic or asymptomatic . . . [Full Text of this Article]


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?

Response to this Correspondence

RESPONSE: Re: A Randomized, Placebo-Controlled Trial of Zoledronic Acid in Patients With Hormone-Refractory Metastatic Prostate Carcinoma
Fred Saad
J Natl Cancer Inst 2004 96: 1183-1184. [Extract] [Full Text] [PDF]